International researchers have broken a new milestone in the treatment of pancreatic cancer, which has been a major challenge in the medical field for decades. 'Daraxonrasib' tablets have given excellent results in clinical trials conducted on 500 patients in severe stage. Research has shown that in addition to a reduction in tumor size, the quality of life of patients has improved in those who have used this drug. Compared to chemotherapy, serious side effects are very less except minor side effects like skin problems and mouth ulcers.
Sanjeevani for Pancreatic Cancer Patients: A New Tablet That Doubles Life!
Scientists have found that the new experimental drug 'Daraxanrasib' in the treatment of the most dangerous metastatic pancreatic cancer significantly increases the life expectancy of patients.
Text size
- This new tablet effectively blocks the mutated protein that causes cancer cells to grow.
- The average life expectancy of those who received regular chemotherapy was 6.7 months, while those who used these pills increased their life expectancy to 13.2 months.






